Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2012 | 02:15pm CEST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media:
Ron Rogers, (908) 423-6449
or
Investors:
Carol Ferguson, (908) 423-4465


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
04/28 SYNDAX PHARMACEUTICALS : Announces Expansion of Immuno-Oncology Collaboration Ev..
04/27 MERCK : New Findings from Merck & Company in Staphylococcus aureus Provides New ..
04/27 MERCK : Researchers from Merck & Company Report New Studies and Findings in the ..
04/27 MERCK : New Hepatitis C Virus Study Results from Merck & Company Described (Anti..
04/27 MERCK : Researchers from Merck & Company Detail New Studies and Findings in the ..
04/27 MERCK : New Findings from Merck & Company Update Understanding of Pain [Kinetic ..
04/27 MERCK : Findings on Antiretrovirals Reported by Researchers at Merck & Company (..
04/27 MERCK : Studies from Merck & Company Have Provided New Information about Rotavir..
04/27 MERCK : Studies from Merck & Company Have Provided New Data on Chronic Kidney Di..
04/27 MERCK : Findings from Merck & Company Reveals New Findings on Osteoporosis (Freq..
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 How Low Can You Go? U.S. Pharma Already Shoulders Light Tax Burden
04/28 Is Bristol-Meyers Squibb A Good Long-Term Pick?
04/28 Merck's Daring Bid For Lung Cancer Domination
04/27 G1 Therapeutics Seeks $115 Million IPO
04/26 GLAXOSMITHKLINE : Good News, 2016's Positive Momentum Continues
Advertisement
Financials ($)
Sales 2017 39 721 M
EBIT 2017 13 570 M
Net income 2017 7 454 M
Debt 2017 3 973 M
Yield 2017 3,01%
P/E ratio 2017 21,80
P/E ratio 2018 18,38
EV / Sales 2017 4,40x
EV / Sales 2018 4,25x
Capitalization 170 880 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,9 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.5.88%170 880
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
SANOFI11.79%121 897
More Results